On November 16, 2020, medical staff examine a patient in the Govit-19 Intensive Care Unit at the United Memorial Medical Center in Houston.
Go Nagamura | Getty Images
LONDON – Swiss biotech company Relief Therapeutics has raised its stake by 38,000% so far this year as it develops a drug that focuses on acute respiratory disorders arising from Covit-19.
Last week, the company, in partnership with US partner NeuroRX, met with an enrollment target of 165 patients agreed with the US Food and Drug Administration in the current 2B / 3 trial of RLF-100, which is a patented version of Aviptadil.
Avipatadil is a synthetic formulation of naturally occurring peptide, which is primarily concentrated in the lungs and works to restore the immune system’s response, and serves as a vasodilator and enhances surfactant production in the lungs. Activating blood oxygen exchange.
RLF-100 has been developed since 2000 to treat acute respiratory distress and other lung conditions, and was later acquired by Biogen. Earlier this year, relief scientists discovered that a cell infected with the Govit-19 virus could be protected.
Speaking to CNBC by phone from New York, Relief Therapist Ram Selvaraju said the ongoing test is expected to provide topline data in the first half of January, and that the meteorite rise in the company’s share price is one reason for the evidence for its effectiveness. Patients who would otherwise be untreatable. “
“While others are primarily focused on those with mild infections or mild illnesses, we quickly sought to see if our drug could benefit the terminally ill and end-stage people,” he said.
Early stage results of extended access application of RLF-100 to patients with complicated Govt-19 and acute comorbidities showed 72% of those admitted to the ICU.
Relief treatments had a market cap of less than 100 million Swiss francs ($ 113 million) at the end of July, following the promising results of the first 21 patients treated with RLF-100 under FDA extended access protocol accreditation on August 10. Surpassed 1.6 billion Swiss. This equates to less than 1 billion Swiss francs.
The 38,000% increase often refers to the small size of the opening stock price, which was as low as 0.40 Swiss francs per share as of Friday afternoon. In contrast, shares of multinational Roach are valued at 306 Swiss francs.
Other therapies used to treat patients have been purchased by government agencies that want to fight the infection, with the U.S. government issuing orders for Operation Warp Speed Gilead’s Remedicivir and Eli Lilly’s Pamlanivimab.
Selvaraju revealed that relief therapies and neuroRX operation were linked to warp speed, and that the company expects to receive stockpiles similar to those of Gilead if the drug successfully demonstrates its effectiveness to critically ill patients following the third phase of randomized testing. And Eli Lily. A spokesman for the U.S. Department of Health and Human Services was not immediately available for comment when contacted by CNBC.
Govind ‘Point of the Glacier’
In June, the FDA provided a rapid path to RLF-100, and the orphanage was named for the treatment of acute respiratory distress syndrome (ARDS).
Since the drug is not an antiviral drug designed to fight the corona virus, Govit-19.
“Govit-19 is actually the tip of the iceberg, the head of the spear. If we can prove that this drug works on Govit-19 related respiratory disorder, we hope that the results can be further tested by drugs in other forms of acute respiratory syndrome that have nothing to do with Govit-19,” Selvaraju said. That said, it puts relief therapy in a “pretty unique position”.
“While many other experimental therapies are going to live or die based on how the infection develops, once the therapeutic application of this drug is established in the context of Covit-19, our long-term vision is for this drug to be used in emergency rooms and intensive care units and in hospitals and hospital settings everywhere. It has to become a kind of labor medicine. “